Quick Answer
Royalty Pharma plc reported Long Term Debt of $8.57 billion for the year ending 2025.
- Royalty Pharma plc showed an increase of +29.6% in Long Term Debt from 2024 to 2025.
- This data is from Royalty Pharma plc's annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $5.73 billion | Q3 2020: $5.81 billion | Q1 2021: $5.82 billion | Q2 2021: $5.83 billion | Q3 2021: $7.09 billion | Q1 2022: $7.10 billion | Q2 2022: $7.11 billion | Q3 2022: $6.11 billion | Q1 2023: $6.12 billion | Q2 2023: $6.13 billion | Q3 2023: $6.13 billion | Q1 2024: $6.14 billion | Q2 2024: $7.60 billion | Q3 2024: $6.61 billion | Q1 2025: $6.62 billion | Q2 2025: $7.00 billion | Q3 2025: $8.57 billion.
- Over the full 7 years of available data (2019 to 2025), Royalty Pharma plc's Long Term Debt has grown by 43.9%.
- Historical annual values: Fiscal year 2025: $8.57 billion | Fiscal year 2024: $6.61 billion | Fiscal year 2023: $6.14 billion | Fiscal year 2022: $6.12 billion | Fiscal year 2021: $7.10 billion | Fiscal year 2020: $5.82 billion | Fiscal year 2019: $5.96 billion.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: